The SARS-CoV-2 pandemic has had an unprecedented impact on multiple levels of society.
Not only has the pandemic completely overwhelmed some health systems but it has also …

Respiratory syncytial virus (RSV) is a leading viral cause of respiratory morbidity and
mortality in infants and young children worldwide. Low and middle income countries (LMICs) …

Background Palivizumab, a monoclonal antibody and the only licensed immunization
product for preventing respiratory syncytial virus (RSV) infection, is recommended for …

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in
young children. A number of mathematical models have been used to assess the cost …

Background Respiratory syncytial virus (RSV) is shown to cause substantial morbidity,
hospitalization, and mortality in infants and older adults. Population-level modeling of RSV …

Introduction COVID-19 related non-pharmaceutical interventions (NPIs) led to a suppression
of RSV circulation in winter 2020/21 in the UK and an off-season resurgence in Summer …

Introduction Respiratory syncytial virus (RSV) is associated with significant morbidity
worldwide, especially among infants. We evaluated the potential impact of prophylactic …

Objectives Model-based cost-effectiveness analyses on maternal vaccine (MV) and
monoclonal antibody (mAb) interventions against respiratory syncytial virus (RSV) use …

The prospect of universal influenza vaccines is generating much interest and research at the
intersection of immunology, epidemiology, and viral evolution. While the current focus is on …

Respiratory syncytial virus (RSV) is a major cause of respiratory morbidity and one of the
main causes of hospitalisation in young children. While there is currently no licensed …